摘要
Abstract
OBJECTIVE: To evaluate the efficacy and safety of Shexiang baoxin pills for patients with coronary disease and angina pectoris. METHODS: We electronically searched CNKI, VIP and CBM. Randomized controlled trials (RCT) on Shexiang baoxin pills in the treatment of coronary disease angina pectoris were selected according to inclusion and exclusion standard then to evaluate the quality of them and extract data. Meta-analysis was conducted using Rev Man 5.0 software. RESULTS: 30 RCTs were included, involving 3 153 patients. Only 2 literature was grade B in quality evaluation, others were all grade C. Meta-analysis showed that: effective rate of angina pectoris attack[OR=3.82, 95%CI(3.15, 4.62), P<0.000 01], effective rate of ECG[OR= 2.50, 95%CI(2.12, 2.94), P<0.000 01], the improvement of ST-segment ischemia[MD= -0.61, 95%CI(-0.88, -0.34), P<0.000 1] and improvement of hemorheology index[MD=-2.15, 95%CI(-2.55, -1.74), P<0.000 01] in trail group was superior to control group, there was statistical significance between 2 groups. The comparison of angina pectoris attack and adverse drug reaction rate[OR=0.57, 95%CI(0.29, 1.11), P=0.10] in trail group was no statistical significance between 2 groups. CONCLUSION : Shexiang baoxin pills can effectively improve the ST segment ischemia and hemorheology index in patients with angina pectoris, significantly increase the effectiveness of ECG review and eventually significantly reduce the recurrence rate of angina pectoris, and appears to be much safer. Due to low quality and small-scale of samples, high quality RCTs are required to provide further reliable evidence for above conclusion.关键词
麝香保心丸/冠心病心绞痛/随机对照试验/Meta分析/系统评价Key words
Shexiang baoxin pills/ Coronary disease angina pectoris/ Randomized controlled trial/ Meta-analysis/ Systematic review分类
医药卫生
